Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Predictive Value of Procalcitonin in Acute Severe Ulcerative Colitis: Not Quite PerfeCT?

Kim DW, An JM, Hong SP, Hahm KB.

Dig Dis Sci. 2019 Feb 7. doi: 10.1007/s10620-019-05481-1. [Epub ahead of print] No abstract available.

PMID:
30734240
2.

Diagnostic value of serum procalcitonin in determining the activity of inflammatory bowel disease.

Oruç N, Ozütemiz O, Osmanoğlu N, Ilter T.

Turk J Gastroenterol. 2009 Mar;20(1):9-12.

3.

Serum Procalcitonin as a Potential Early Predictor of Short-Term Outcomes in Acute Severe Ulcerative Colitis.

Wu HM, Wei J, Li J, Wang K, Ye L, Qi Y, Yuan BS, Yang YL, Zhao L, Yang Z, Yang MF, Gong JF, Wang FY.

Dig Dis Sci. 2019 Jan 2. doi: 10.1007/s10620-018-5446-0. [Epub ahead of print]

PMID:
30604378
4.

Clinical importance of serum procalcitonin in ulcerative colitis patients.

Karagoz E, Tanoglu A.

World J Gastroenterol. 2014 Nov 14;20(42):15941-2. doi: 10.3748/wjg.v20.i42.15941.

5.

Faecal analysis and plasma complement factor 3c levels at admission for an acute attack of ulcerative colitis are predictive of the need for colectomy.

Pagoldh M, Lange S, Jennische E, Almer S, Boström EA, Eriksson A.

Eur J Gastroenterol Hepatol. 2014 Mar;26(3):295-300. doi: 10.1097/MEG.0000000000000042.

PMID:
24418832
6.

Colectomy rate in acute severe ulcerative colitis in the infliximab era.

Aratari A, Papi C, Clemente V, Moretti A, Luchetti R, Koch M, Capurso L, Caprilli R.

Dig Liver Dis. 2008 Oct;40(10):821-6. doi: 10.1016/j.dld.2008.03.014. Epub 2008 May 9.

PMID:
18472316
7.

Clinical significance of serum procalcitonin in patients with ulcerative colitis.

Koido S, Ohkusa T, Takakura K, Odahara S, Tsukinaga S, Yukawa T, Mitobe J, Kajihara M, Uchiyama K, Arakawa H, Tajiri H.

World J Gastroenterol. 2013 Dec 7;19(45):8335-41. doi: 10.3748/wjg.v19.i45.8335.

8.

[Frequency and predictive factors of colectomy and restorative colo-proctectomy in ulcerative colitis].

Karoui S, Serghini M, Chaieb M, Jomni T, Kallel L, Fekih M, Matri S, Boubaker J, Filali A.

Tunis Med. 2009 Feb;87(2):115-9. French.

9.
11.

Predictive value of inflammatory and coagulation parameters in the course of severe ulcerative colitis.

Linskens RK, van Bodegraven AA, Schoorl M, Tuynman HA, Bartels P.

Dig Dis Sci. 2001 Mar;46(3):644-8.

PMID:
11318546
12.

Severe eosinophilic infiltration in colonic biopsies predicts patients with ulcerative colitis not responding to medical therapy.

Zezos P, Patsiaoura K, Nakos A, Mpoumponaris A, Vassiliadis T, Giouleme O, Pitiakoudis M, Kouklakis G, Evgenidis N.

Colorectal Dis. 2014 Dec;16(12):O420-30. doi: 10.1111/codi.12725.

PMID:
25040651
13.

Fecal calprotectin as an alternative to ulcerative colitis endoscopic index of severity to predict the response to corticosteroids of acute severe ulcerative colitis: A prospective observational study.

Xie T, Zhao C, Ding C, Zhang T, Dai X, Lv T, Li Y, Guo Z, Gong J, Zhu W.

Dig Liver Dis. 2017 Sep;49(9):984-990. doi: 10.1016/j.dld.2017.04.021. Epub 2017 May 3.

PMID:
28539226
14.

Differentiating Clostridium difficile Colitis from Clostridium difficile Colonization in Ulcerative Colitis: A Role for Procalcitonin.

Reinink AR, Limsrivilai J, Reutemann BA, Feierabend T, Briggs E, Rao K, Higgins PDR.

Digestion. 2017 Oct 14;96(4):207-212. doi: 10.1159/000481133. [Epub ahead of print]

PMID:
29032373
15.

Additional benefit of procalcitonin to C-reactive protein to assess disease activity and severity in Crohn's disease.

Oussalah A, Laurent V, Bruot O, Guéant JL, Régent D, Bigard MA, Peyrin-Biroulet L.

Aliment Pharmacol Ther. 2010 Nov;32(9):1135-44. doi: 10.1111/j.1365-2036.2010.04459.x. Epub 2010 Sep 16.

16.

The effect of pre-admission immunosuppression on colectomy rates in acute severe ulcerative colitis.

Patrick D, Doecke J, Irwin J, Hanigan K, Simms L, Howlett M, Radford-Smith G.

Therap Adv Gastroenterol. 2018 Nov 13;11:1756284818809789. doi: 10.1177/1756284818809789. eCollection 2018.

17.

Review article: applying pharmacokinetics to optimise dosing of anti-TNF biologics in acute severe ulcerative colitis.

Rosen MJ, Minar P, Vinks AA.

Aliment Pharmacol Ther. 2015 Jun;41(11):1094-103. doi: 10.1111/apt.13175. Epub 2015 Mar 23. Review.

18.

Management of Acute Severe Colitis in Children With Ulcerative Colitis in the Biologics Era.

Romano C, Syed S, Valenti S, Kugathasan S.

Pediatrics. 2016 May;137(5). pii: e20151184. doi: 10.1542/peds.2015-1184. Review.

19.

Predictive factors for a severe clinical course in ulcerative colitis: Results from population-based studies.

Wanderås MH, Moum BA, Høivik ML, Hovde Ø.

World J Gastrointest Pharmacol Ther. 2016 May 6;7(2):235-41. doi: 10.4292/wjgpt.v7.i2.235. Review.

20.

Serum procalcitonin differentiates inflammatory bowel disease and self-limited colitis.

Herrlinger KR, Dittmann R, Weitz G, Wehkamp J, Ludwig D, Schwab M, Stange EF, Fellermann K.

Inflamm Bowel Dis. 2004 May;10(3):229-33.

PMID:
15290916

Supplemental Content

Support Center